Highlights

  • Continuing-operations revenue reached $7.2m in H1 FY26, compared with $6.8m in H1 FY25.
  • Gross margin on continuing operations increased from 33.5% to 43.2%.
  • Operating expenses decreased by $1.1m, or 25%, to $3.3m.
  • The company completed the sale of its US business on 4 September 2026.
  • Australian nutrition, ingredients and retail distribution are central to the revised business plan.

Elixinol Wellness Limited (ASX:EXL) develops and distributes nutrition, wellness and food-ingredient products, with Australian brands including Hemp Foods Australia, The Healthy Chef and Mt Elephant. Following its September 2026 US business divestment, the company has outlined an increased focus on its Australian consumer brands, ingredient supply and retail channels. Its H1 FY26 disclosures provide the financial context for this portfolio change.

Half-Year Revenue and Margins

Elixinol Wellness Limited (ASX:EXL) reported continuing-operations revenue of $7.2m for the six months ended 30 June 2026, up 5.8% from $6.8m in H1 FY25. The reported gross margin increased to 43.2% from 33.5%, a 9.8 percentage-point movement. These measures relate to the continuing business rather than operations subsequently sold.

The adjusted EBITDA loss on continuing operations narrowed to $0.1m from $2.1m in the comparable period. The group also reported a statutory loss after tax of $1.1m, compared with $3.1m in H1 FY25. Those results reflect changes in the cost base as well as sales performance; they do not represent a full-year profit outcome.

Changes to the Operating Portfolio

The US divestment, completed on 4 September 2026, transferred Elixinol LLC under a transaction with headline consideration of A$465,000. The terms comprised A$250,000 on completion and deferred, contingent and earn-out components. Elixinol Wellness Limited (ASX:EXL) retained rights to the Elixinol brand outside the United States, while the transaction reduced its direct exposure to that market.

The Australian portfolio includes Hemp Foods Australia and its ingredients activities, together with The Healthy Chef and Mt Elephant. Company materials identify grocery, pharmacy, e-commerce, business-to-business supply and private-label activity as areas of operational focus. These channels have different customers and distribution requirements, making sales mix and fulfilment costs relevant to future reporting.

Operating Costs, Funding and Cash Position

During H1 FY26, Elixinol Wellness Limited (ASX:EXL) reduced operating expenses by $1.1m, or 25%, to $3.3m. The company attributed the reduction to employee, marketing, distribution and administration costs. The group reported receipts from customers of $7.42m, compared with $7.95m in H1 FY25, showing that cash collections and recognised revenue did not move in the same direction.

At 30 June 2026, cash and cash equivalents were $996,000, compared with $1,405,000 at 31 December 2025. Net assets were $6.4m against $7.5m at the previous year-end. The subsequent convertible note issue raised A$1.06m, with a 12% annual coupon and stated maturity on 31 December 2027. The financing brings interest obligations and potential future conversion into the capital structure.

What the Business Plan Covers

Elixinol Wellness Limited (ASX:EXL) identified retail distribution initiatives in its H2 FY26 plan, including a Priceline rollout, Mt Elephant grocery distribution and hemp-ingredient supply to two major retailers. The longer-term plan in its September presentation includes functional nutrition products, private-label activity and selective acquisitions. These are company-stated priorities, not confirmed future sales or earnings.

The distinction between product initiatives and realised commercial outcomes is important. Launches and distribution agreements are operational steps; their financial impact depends on actual orders, production costs, consumer demand and repeat sales. The September update did not establish that every initiative would deliver a specified revenue contribution.

Key Insights

The 2026 reporting period marks a change in Elixinol Wellness Limited (ASX:EXL)’s business composition. Higher reported continuing-operations margins and lower operating expenses coincided with a statutory loss, reduced cash at half-year end and new convertible funding. The US divestment directs attention towards the operating performance of Australian nutrition brands and ingredients distribution. Future company disclosures will show how that narrower portfolio translates into revenue, expenses and cash flow.